Evidence map›Paper›PMID 31126213›Full record

ArticleLupus2019

Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation.

A Albay, B Artim-Esen, C Pericleous, C Wincup, I Giles, A Rahman, T McDonnell

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

A Albay1 Centre for Rheumatology Research, Division of Medicine, University College London, Department of Medicine, Rayne Institute, London, UK.
B Artim-Esen2 Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.ORCID https://orcid.org/0000-0002-5659-3955
C Pericleous3 Imperial College London, Imperial College Vascular Sciences, National Heart & Lung Institute, ICTEM, London, UK.
C Wincup1 Centre for Rheumatology Research, Division of Medicine, University College London, Department of Medicine, Rayne Institute, London, UK.ORCID https://orcid.org/0000-0002-8742-8311
I Giles1 Centre for Rheumatology Research, Division of Medicine, University College London, Department of Medicine, Rayne Institute, London, UK.
A Rahman1 Centre for Rheumatology Research, Division of Medicine, University College London, Department of Medicine, Rayne Institute, London, UK.
T McDonnell1 Centre for Rheumatology Research, Division of Medicine, University College London, Department of Medicine, Rayne Institute, London, UK.ORCID https://orcid.org/0000-0002-1712-9957
University College London · GBImperial College London · GBIstanbul University · TR

Funding

Medical Research Council MR/P017371/1Versus Arthritis 19423Versus Arthritis 21223Versus Arthritis 21992
6 · The paper itself

Abstract

objectivesThis study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA anti-beta-2-glycoprotein I (aβ2GPI) binding using Domain I (DI).

methodsSerum from 13 APS patients was tested for IgA aβ2GPI and Anti-Domain I. Whole IgA was purified by peptide M affinity chromatography from positive serum samples. Serum was tested for IgA aβ2GPI binding in the presence and absence of either DI or of two biochemically modified variants containing either 20 kDa of poly(ethylene glycol) (PEG) or 40 kDa of PEG.

resultsSignificant inhibition with DI was possible with average inhibition of 23% (

conclusionsInhibition of IgA aβ2GPI by DI is possible and can be enhanced by biochemical modification in a subset of patients.

Indexed as

Antibodies, AntiphospholipidAntiphospholipid Syndromebeta 2-Glycoprotein IEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin ALondonLupus Coagulation InhibitorLupus Erythematosus, SystemicMaleOxidation-ReductionTurkeyAntibodies, Antiphospholipidbeta 2-Glycoprotein IImmunoglobulin ALupus Coagulation InhibitorAntiphospholipid syndromeDomain IPEGylation

Identifiers

PMID31126213
PMCPMC6567316
OpenAlexW2944867446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.